Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.79 |
| ▸ | ALPI | P09923 | 1/20 | 0.79 |
| ▸ | PKM | P14618 | 1/20 | 0.79 |
| ▸ | XIAP | P98170 | 1/20 | 0.79 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL3951720 | 1.00 | SLC7A5 (0.79) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL7420158 | 0.98 | SLC7A5 (0.76) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL28138410 | 0.91 | SLC7A5 (0.88) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL5063628 | 0.89 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL5063626 | 0.89 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 0.89 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.89 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 0.89 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16398197 | 0.89 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL837632 | 0.89 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3806918-A1 | STABILIZED HYALURONIC ACID | Croma-Pharma Gesellschaft m.b.H. (AT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238955-A1 | STABILIZED HYALURONIC ACID | CROMA-PHARMA GMBH (AT) | 2019-12-19 | — | — | WO | claimed |
| WO-2010003037-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR STABILIZATION OF A CELL AND/OR MACROMOLECULE | SIERRA MOLECULAR CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| EP-4326353-A1 | ENHANCED ANTIMICROBIAL EFFICACY (SYNERGY) OF SILVER AND COPPER COMPOUNDS AND MEDICAL USE OF THEIR COMBINATIONS | Nanordica Medical Oü (EE) | 2024-02-28 | — | — | EP | disclosed |
| US-20230295344-A1 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-09-21 | — | — | US | disclosed |
| WO-2022266368-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11530276-B2 | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-12-20 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| EP-3930749-A1 | MULTIVALENT LIVE-ATTENUATED INFLUENZA VACCINE FOR PREVENTION AND CONTROL OF EQUINE INFLUENZA VIRUS (EIV) IN HORSES | University of Rochester (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021251827-A1 | MEANS AND METHODS FOR DETECTING, PRODUCING, ISOLATING OR CHARACTERIZING INFLUENZA | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2021-12-16 | — | — | WO | disclosed |
| US-20210206876-A1 | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | 4TEEN4 Pharmaceuticals GmbH (DE) | 2021-07-08 | — | — | US | disclosed |
| WO-1995000850-A1 | A NOVEL FAMILY OF POLLEN PROTEINASES, METHODS OF USE THEREOF AND COMPOSITIONS DERIVED THEREFROM | LXR BIOTECHNOLOGY INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994026786-A1 | COMPOSITIONS COMPRISING COMPLEMENT RELATED PROTEINS AND CARBOHYDRATES, AND METHODS FOR PRODUCING AND USING SAID COMPOSITIONS | T CELL SCIENCES, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994014070-A1 | IMMUNOASSAY FOR THE MEASUREMENT OF COLLAGEN CLEAVAGE IN CARTILAGE | SHRINERS HOSPITALS FOR CRIPPLED CHILDREN (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1994007919-A9 | INSULIN RECEPTOR-LIKE PROTEIN | — | 1994-05-26 | — | — | WO | disclosed |
| EP-0276262-A4 | MEROZOITE SURFACE ANTIGEN OF -i(PLASMODIUM) -i(FALCIPARUM). | SARAMANE PTY LTD (AU) | 1989-09-19 | — | — | EP | disclosed |
| EP-0321526-A1 | CLONING AND EXPRESSION OF HUMAN TISSUE FACTOR | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988009817-A1 | CLONING AND EXPRESSION OF HUMAN TISSUE FACTOR | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERS (US) | 1988-12-15 | — | — | WO | disclosed |
| EP-0276262-A1 | MEROZOITE SURFACE ANTIGEN OF -i(PLASMODIUM) -i(FALCIPARUM). | SARAMANE PTY LTD (AU) | 1988-08-03 | — | — | EP | disclosed |
| WO-1988000595-A1 | MEROZOITE SURFACE ANTIGEN OF PLASMODIUM FALCIPARUM | SARAMANE PTY. LTD. (AU) | 1988-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530276-B2 | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | DPP3, DPP4, DPP7 | SLC7A5 3178/4885PTGS1 3792/4885ALPI 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.